Jul 10, 2023 / 03:00PM GMT
Ritu Subhalaksmi Baral - TD Cowen, Research Division - MD & Senior Biotechnology Analyst
Hi, everyone. Thanks for joining us today for the Sarepta fireside chat at TD Cowen's Second Annual RNA Therapeutics Summit. With us for the fireside chat, we have Sarepta's CEO, Doug Ingram. Also on the line if we need him, we have CFO, Ian Estepan.
Thank you so much, Doug, for joining us today. Busy times for you guys, but I did want to take the time today to focus on what is really your foundational technology from back in the day and the foundation for base business, the PMO and PPMO DMD therapies. There's been a lot of discussion about your newly approved DMD gene therapy, ELEVIDYS certainly. But then it turns to what will become of your close to $1 billion DMD PMO franchise and your PPMO pipeline for DMD going forward.
So Doug, let's start on a high level. What are the aspects of AAV gene therapies as you see it, that you think RNA therapies, particularly your PPMOs could address?
Sarepta Therapeutics Inc at TD Cowen RNA Therapeutics Summit (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers